Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Deffered Revenue (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $347.9 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Deffered Revenue rose 1.19% year-over-year to $347.9 million; the TTM value through Mar 2026 reached $347.9 million, up 1.19%, while the annual FY2025 figure was $350.1 million, 5.06% up from the prior year.
  • Non-Current Deffered Revenue hit $347.9 million in Q1 2026 for Phathom Pharmaceuticals, down from $350.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $350.1 million in Q4 2025 and bottomed at $109.5 million in Q4 2022.
  • Average Non-Current Deffered Revenue over 5 years is $282.3 million, with a median of $322.4 million recorded in 2024.
  • Year-over-year, Non-Current Deffered Revenue surged 173.74% in 2023 and then grew 1.19% in 2026.
  • Phathom Pharmaceuticals' Non-Current Deffered Revenue stood at $109.5 million in 2022, then skyrocketed by 173.74% to $299.8 million in 2023, then increased by 11.16% to $333.3 million in 2024, then increased by 5.06% to $350.1 million in 2025, then fell by 0.64% to $347.9 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $347.9 million, $350.1 million, and $349.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.